Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today reported on the first three months of fiscal year 2026 (1 December 2025 – 28 February 2026) and the Group’s financial figures.
– Phase I part of the clinical trial with pamlectabart tismanitin (HDP-101) in multiple myeloma completed
– Dose determined for Phase IIa part, and first patient dosed
– Start of clinical development in Takeda’s and Huadong’s partner projects; milestone payments to Heidelberg Pharma triggered
– Amendment to the agreement with HealthCare Royalty and investment by Soleus Capital: Payment of USD 20 million extends cash reach to mid-2027
– Financial figures in line with forecast